![John Kastelein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 3 Mio $ am 31.05.2026
John Jacob Pieter Kastelein is the founder of NewAmsterdam Pharma Holding BV, founded in 2019, where the title held is Chief Scientific Officer & Executive Director.
Dr. Kastelein is the founder of NewAmsterdam Pharma Corp., founded in 2019, where the title held is Chief Scientific Officer & Executive Director.
Current jobs include Chief Executive Officer at Vascular Research Network B V since 2013; Chairman-Vascular Medicine Department at Academisch Medisch Centrum; Director at NorthSea Therapeutics BV; Director at Oxitope Pharma BV; Non-Executive Director & Chief Scientific Officer at NewAmsterdam Pharma Co. NV since 2022; Emeritus Professor-Medicine at the University of Amsterdam; Operating Partner at Forbion Capital Partners Management Holding BV; President at Dutch Atherosclerosis Society; President-National Scientific Committee at Familial Hypercholesterolemia Foundation; and Chief Medical Officer at Staten Biotechnology BV since 2018.
Education includes a doctorate from the University of Amsterdam.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.04.2026 | 74’636 ( 0.06% ) | 3 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2022 |
Academisch Medisch Centrum
 Academisch Medisch Centrum Hospital/Nursing ManagementHealth Services Operates as a medical center and provides scientific research & education services for next generation of healthcare professionals | Corporate Officer/Principal | - |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Gründer | 01.01.2019 |
Oxitope Pharma BV
 Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Manufactures medicines for the treatment of inflammatory and cardiovascular diseases | Direktor/Vorstandsmitglied | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | - |
Staten Biotechnology BV
 Staten Biotechnology BV BiotechnologyHealth Technology Develops novel therapies | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Direktor/Vorstandsmitglied | - |
University of Amsterdam
 University of Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Dutch Atherosclerosis Society | Präsident | - |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░ ░ ░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Academisch Medisch Centrum
Academisch Medisch Centrum Hospital/Nursing ManagementHealth Services Operates as a medical center and provides scientific research & education services for next generation of healthcare professionals | Health Services |
University of Amsterdam
University of Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Dutch Atherosclerosis Society | |
Familial Hypercholesterolemia Foundation
 Familial Hypercholesterolemia Foundation Miscellaneous Commercial ServicesCommercial Services The Familial Hypercholesterolemia Foundation focuses on the inherited condition known as familial hypercholesterolemia (FH), which causes high levels of low-density lipoprotein cholesterol (LDL-C) at an early age. The non-profit company is based in Pasadena, CA. FH is estimated to affect 1 million people in the United States, but less than 10% are diagnosed. Heterozygous FH (HeFH) is the more common type and occurs in approximately 1 in 250 people, with a 50% chance of passing the condition to their offspring. | Commercial Services |
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Develops novel therapies | Health Technology |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Health Technology |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Health Technology |
Oxitope Pharma BV
Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Manufactures medicines for the treatment of inflammatory and cardiovascular diseases | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
NewAmsterdam Pharma Corp.
 NewAmsterdam Pharma Corp. BiotechnologyHealth Technology Develops therapies in the fields of metabolic diseases, cardiovascular diseases, and liver diseases | Health Technology |
Vascular Research Network B V |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
